SCHEMBL3835233

SCHEMBL3835233

NC(=O)CCCc1cc(O)ccc1O.O=C(O)CCCCc1cc(O)ccc1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F13A1 P00488 3/20 0.49
EGFR P00533 2/20 0.47
LCK P06239 1/20 0.47
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 2/20 0.41
TP53 P04637 2/20 0.41
CYP3A4 P08684 2/20 0.41
ALOX15 P16050 2/20 0.41
TYR P14679 2/20 0.41
ALOX5 P09917 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
POLB P06746 1/20 0.41
LTB4R Q15722 1/20 0.41
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7785687 0.94 EGFR (0.47) F13A1EGFRLCKMEN1KMT2A
SCHEMBL7794268 0.92 EGFR (0.49) EGFRLCKMEN1KMT2AMAPT
SCHEMBL6582394 0.92 F13A1 (0.56) F13A1EGFRLCKMEN1KMT2A
SCHEMBL3840098 0.90 F13A1 (0.59) F13A1EGFRLCKMEN1KMT2A
SCHEMBL4148828 0.90 F13A1 (0.59) F13A1EGFRLCKMEN1KMT2A
SCHEMBL3838231 0.90 F13A1 (0.59) F13A1EGFRLCKMEN1KMT2A
SCHEMBL2381980 0.90 F13A1 (0.59) F13A1EGFRLCKMEN1KMT2A
SCHEMBL3842422 0.90 EGFR (0.54) F13A1EGFRLCKTP53CYP3A4
SCHEMBL8764494 0.83 TYR (0.59) F13A1MEN1KMT2AMAPTTP53
SCHEMBL8764373 0.80 TYR (0.63) MEN1KMT2AMAPTTP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8505730-B2 Compositions, kits and regimens for the treatment of skin, especially décolletage JR CHEM, LLC (US) 2013-08-13 US disclosed
US-20120312717-A1 COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE JR CHEM, LLC (US) 2012-12-13 US disclosed
US-8273791-B2 Compositions, kits and regimens for the treatment of skin, especially décolletage JR CHEM, LLC (US) 2012-09-25 US disclosed
EP-2087880-A2 Compositions, kits and regimens for the treatment of skin, especially décolletage Jr Chem, LLC (US) 2009-08-12 EP disclosed
US-20090176876-A1 COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE JR CHEM, LLC (US) 2009-07-09 US disclosed
US-6960347-B2 Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives L'OREAL (FR) 2005-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176876-A1 COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE RARG, RARA, RXRG F13A1 868/4885EGFR 1252/4885LCK 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.